A 2023 study from Washington University in St. Louis found that suvorexant, an FDA-approved insomnia drug, reduced levels of amyloid-beta and tau proteins linked to Alzheimer’s disease in the cerebrospinal fluid of healthy middle-aged adults. Over two nights, participants taking a higher dose (20 mg) showed a 10-20% decrease in amyloid-beta and a 10-15% reduction in phosphorylated tau compared to a placebo group. These proteins are associated with Alzheimer’s pathology, as their buildup forms plaques and tangles that impair brain function.
However, the study was small (38 participants), short-term, and didn’t improve sleep quality or duration. The protein reductions were temporary, with levels rising again within 24 hours. Researchers, including lead author Dr. Brendan Lucey, caution against using suvorexant as an Alzheimer’s preventive, as long-term effects are unknown. They are now conducting trials to explore extended use in at-risk individuals with amyloid plaques.
The findings suggest a link between sleep and Alzheimer’s proteins but don’t confirm suvorexant as a treatment. Improving sleep hygiene or addressing disorders like sleep apnea may support brain health, though more research is needed.
Source:
https://www.nih.gov/news-events/nih-research-matters/insomnia-drug-may-lower-levels-alzheimers-proteins
https://www.sciencealert.com/a-common-sleeping-pill-may-reduce-build-up-of-alzheimers-proteins-study-finds)
